LMR Partners LLP Makes New Investment in InMode Ltd. (NASDAQ:INMD)

LMR Partners LLP acquired a new stake in InMode Ltd. (NASDAQ:INMD - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 17,332 shares of the healthcare company's stock, valued at approximately $289,000.

Other large investors have also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. acquired a new position in InMode in the 4th quarter valued at approximately $87,000. Farther Finance Advisors LLC increased its stake in InMode by 26.2% in the 4th quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company's stock valued at $93,000 after buying an additional 1,154 shares during the period. Covestor Ltd increased its stake in shares of InMode by 13.9% during the 4th quarter. Covestor Ltd now owns 5,936 shares of the healthcare company's stock worth $99,000 after purchasing an additional 723 shares during the last quarter. Pilgrim Partners Asia Pte Ltd acquired a new position in shares of InMode during the 4th quarter worth $114,000. Finally, Quarry LP increased its stake in shares of InMode by 100.0% during the 4th quarter. Quarry LP now owns 7,561 shares of the healthcare company's stock worth $126,000 after purchasing an additional 3,780 shares during the last quarter. Institutional investors and hedge funds own 68.04% of the company's stock.

InMode Price Performance

NASDAQ:INMD traded up $0.28 during midday trading on Tuesday, reaching $14.81. The stock had a trading volume of 254,464 shares, compared to its average volume of 1,184,148. InMode Ltd. has a 1-year low of $13.68 and a 1-year high of $19.85. The firm's fifty day simple moving average is $15.92 and its 200-day simple moving average is $17.32. The stock has a market capitalization of $1.03 billion, a P/E ratio of 6.29 and a beta of 2.02.

InMode (NASDAQ:INMD - Get Free Report) last posted its earnings results on Monday, April 28th. The healthcare company reported $0.31 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by ($0.14). InMode had a net margin of 45.91% and a return on equity of 18.25%. The firm had revenue of $77.87 million during the quarter, compared to analyst estimates of $82.21 million. During the same quarter in the previous year, the business posted $0.32 earnings per share. The business's quarterly revenue was down 3.0% compared to the same quarter last year. On average, equities research analysts anticipate that InMode Ltd. will post 1.75 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. UBS Group dropped their price target on shares of InMode from $19.00 to $16.25 and set a "neutral" rating on the stock in a research note on Tuesday, April 29th. Needham & Company LLC restated a "hold" rating on shares of InMode in a research note on Monday, April 28th. Baird R W lowered shares of InMode from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 28th. Jefferies Financial Group dropped their price target on shares of InMode from $16.00 to $15.00 and set a "hold" rating on the stock in a research note on Monday, April 14th. Finally, BTIG Research lowered shares of InMode from a "buy" rating to a "neutral" rating in a research note on Tuesday, April 29th. Seven analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $18.54.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.